Biologic immunomodulators prior authorization
Customize your policy alerts
Sign up for all mediviewcurative policy alerts
Know when mediviewcurative releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization coverage criteria and approval durations for specified biologic immunomodulator drugs when used for compendia-supported indications across multiple immune-mediated diseases; applies to providers submitting PA requests to Curative Health Plan.
No material clinical or coverage changes in this revision.
Coverage Criteria and Medical Necessity
General coverage
Covered when ALL of the following are met for a compendia-supported indication:
General PA rule
- Indication-specific criteria: One of the indication-specific sets below must be satisfied
Chart notes within past 6 months for initial therapy; see specific indication criteria
Initial Therapy - Rheumatoid Arthritis
Rheumatoid Arthritis (Initial Therapy) - Covered when ALL of the following are met:
Chart notes within past 6 months
Initial Therapy - Psoriatic Arthritis
Psoriatic Arthritis (Initial Therapy) - Covered when ANY of the following meet criteria:
Chart notes within past 6 months
Initial Therapy - Plaque Psoriasis
Moderate to Severe Plaque Psoriasis (Initial Therapy) - Covered when ALL are met:
Chart notes within past 6 months
Initial Therapy - Hidradenitis Suppurativa
Hidradenitis Suppurativa (Initial Therapy) - Covered when ALL are met:
Chart notes within past 6 months
Initial Therapy - Crohn's Disease
Crohn's Disease (Initial Therapy) - Covered when ALL are met:
Chart notes within past 6 months
Initial Therapy - Ulcerative Colitis
Ulcerative Colitis (Initial Therapy) - Covered when ALL are met:
Chart notes within past 6 months
Initial Therapy - Uveitis
Uveitis (Initial Therapy) - Covered when ALL are met:
Chart notes within past 6 months
Initial Therapy - Ankylosing Spondylitis
Ankylosing Spondylitis (Initial Therapy) - Covered when ALL are met:
Approval duration may differ by member type
Initial Therapy - Non-radiographic axial SpA
Non-radiographic axial spondyloarthritis (Initial Therapy) - Covered when ALL are met:
Chart notes within past 6 months
Initial Therapy - Juvenile Idiopathic Arthritis
PJIA & SJIA (Initial Therapy) - Covered when ALL are met:
Chart notes within past 6 months
Chart notes within past 6 months
Initial Therapy - SSc-ILD and GCA
SSc-ILD & GCA (Initial Therapy) - Covered when ALL are met:
Chart notes within past 6 months
Chart notes within past 6 months
Continued Therapy Criteria
Continuation/renewal (Continued Therapy) - Covered when ALL of the following are met:
Chart notes within past 12 months
Continued Therapy (all listed indications)
Covered when ALL of the following are met for the specific indication
Apply indication-specific examples of clinical benefit as listed in source chunks (e.g., Hurley stage for HS; CDAI for Crohn's; UCEIS/CRP/FC for UC; slit lamp findings for uveitis; decreased back pain/function and CRP for axial disease).
Requests for biologic immunomodulator therapy will be excluded from approval when the medication is not being used for a compendia‑supported indication or when required documentation for the requested indication is not provided. The policy requires that the requested drug represent therapy for a listed, evidence‑supported diagnosis and that supporting chart notes and objective data be submitted to validate that indication.
Requests lacking required prior trials or objective baseline disease documentation may be considered not medically necessary. For initial therapy most indications require documented trial and failure of conventional therapy for at least 3 months (or shorter specified durations where noted) and diagnostic testing or baseline disease measures (e.g., ESR/CRP, RF/anti‑CCP, imaging, CDAI/RAPID3/DAS28) must validate the diagnosis. For continuation, absence of evidence of clinical benefit in chart notes (e.g., improved functional scores, decreased symptoms) within the required timeframe can render the request not medically necessary.
Requests that do not document prior benefit from the requested agent, that lack involvement of a relevant specialist (or documentation of specialist consultation), or that propose combination use with another immunomodulatory agent without submission of full supporting evidence (e.g., published peer‑reviewed trials or national guideline references) may be denied. The policy requires attestation of prior benefit for continuation requests and full documentation to justify any combination immunotherapy.
Listed Products and Coding Context
| Adalimumab-fkjp | listed biologic agent |
| Adalimumab-adbm | listed biologic agent |
| 80mg Adalimumab-aaty | listed biologic agent |
| Tyenne (tocilizumab-aazg) | listed biologic agent |
| Yesintek (ustekinumab-kfce) | listed biologic agent |
| Imuldosa (ustekinumab-srlf) | listed biologic agent |
Provider Requirements, Prior Authorization, and Denials
Prior authorization required for listed biologics
Prior authorization is required for listed biologic immunomodulator products when the medication is being used for a compendia‑supported indication and all indication‑specific criteria are met. Submit a PA request and supporting documentation demonstrating the requested agent and indication satisfy the policy's criteria.
- Applies to the listed biologic agents in the policy.
- PA must demonstrate compendia‑supported indication and satisfy the specific initial or continued therapy criteria.
Continuation approvals are for 12 months
If continued‑therapy criteria are met (patient previously met initial criteria or chart notes within past 12 months document ongoing benefit and attest continuation), prior authorization for continuation is approved for 12 months.
- Approval duration standard: 12 months for continuation across listed indications.
- Document chart notes from the past 12 months showing the drug is a continuation with clinical benefit.
Step therapy: required prior trials and durations
Most indications require trial and failure of specified conventional therapies prior to biologic approval; typical minimum durations are at least 3 months for many indications, at least 4 weeks of NSAID therapy for axial disease, and at least 1 month of NSAID therapy for SJIA.
- ≥3 months trial and failure of conventional therapy (e.g., methotrexate, azathioprine, 6‑MP) for many indications.
- ≥4 weeks trial and failure of NSAIDs for ankylosing spondylitis and nr‑axSpA.
- ≥1 month NSAID trial for systemic juvenile idiopathic arthritis (SJIA).
Continued therapy requires prior criteria met or documented benefit
Continued therapy approvals require that the patient previously met the initial criteria for the requested agent or that chart notes within the past 12 months document the patient has been on the requested drug with clinical benefit and the prescriber attests the request is for continuation of therapy.
- Prescriber must document prior meeting of initial criteria OR supply chart notes within past 12 months showing ongoing therapy with benefit and attestation of continuation.
- Continued therapy also requires documented clinical benefit appropriate to the indication and specialist involvement or consultation.
Submit recent chart notes with diagnosis‑specific baseline tests
Provide chart notes within the past 6–12 months demonstrating diagnosis‑specific baseline testing and results that validate the diagnosis (examples include ESR/CRP, RF/anti‑CCP, imaging, disease activity scores, endoscopy findings, Hurley stage where applicable).
- Include objective baseline measures cited by indication (e.g., CDAI or endoscopy for Crohn's; UCEIS, CRP/FC for UC; Hurley stage and lesion counts for HS; ophthalmic findings for uveitis).
- Chart notes that establish baseline testing should be from within the past 6 months for initial therapy; continued therapy documentation may reference past 12 months as specified.
Document prior use with clinical benefit for continuation
For continuation requests, submit chart notes within the past 12 months demonstrating the patient has been on the requested drug with clinical benefit and include an attestation that the request is for continuation of therapy.
- Document indication‑appropriate clinical benefit (e.g., improved CDAI, decreased CRP/FC, improved Hurley stage, improved visual findings).
- Include a prescriber attestation that the request is for continuation of therapy.
Provide full supporting evidence for combination immunomodulatory therapy
If requesting use of a biologic in combination with another immunomodulatory agent, submit full supporting documentation such as published peer‑reviewed clinical trials or national guideline recommendations; chart notes alone are insufficient without explicit supporting evidence.
- Provide the specific evidence supporting the combination (peer‑reviewed trials or guidelines).
- Policy requires full documentation to justify combination therapy to avoid denial.
Denial risk: unsupported indication or missing documentation
Requests will be denied if the requested medication is not being used for a compendia‑supported indication or if required documentation and indication‑specific criteria are not met.
- Ensure the indication is compendia‑supported and all initial or continued therapy criteria are satisfied.
- Missing required documentation (baseline tests, prior trials, specialist involvement/attestation) risks denial.
Denial triggers: no prior benefit, no specialist, unsupported combination
Denial may be triggered by lack of documentation of prior benefit from the requested agent, absence of a specialist prescriber or documented specialist consultation, or if the record indicates combination therapy without supporting evidence for the combination.
- For continuation, chart notes must show prior clinical benefit; absence of this documentation can trigger denial.
- Prescriber must be a specialist or have documented consultation in the specialty area.
- Combination use without submitted supporting trials/guidelines may lead to denial.
Definitions and Diagnostic Documentation
Background and Scope
This policy addresses use of biologic immunomodulators across a range of immune‑mediated inflammatory diseases and defines prior authorization requirements, indication‑specific initiation criteria, and continued‑therapy documentation expectations. For each listed diagnosis the plan requires objective baseline disease documentation, prior trial/failure of specified conventional therapies or similarly‑indicated biologics (unless contraindicated), and prescriber specialty involvement or consultation to support approval decisions.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.